What laboratory side effects are associated with daratumumab therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Laboratory Side Effects of Daratumumab

Daratumumab causes false-positive indirect Coombs tests and can interfere with serum immunofixation results, requiring type and screen before treatment initiation. 1

Critical Laboratory Interferences

Blood Bank Testing Interference

  • Daratumumab binds to CD38 on red blood cells, causing false-positive indirect antiglobulin tests (indirect Coombs test) 1
  • Mandatory action: Perform complete type and screen before initiating daratumumab therapy 1
  • This interference masks detection of minor antigen antibodies in patient serum and disrupts serologic testing 1
  • Cross-matching workaround: Dithiothreitol (DTT) treatment of reagent erythrocytes reliably eliminates daratumumab interference, but removes Kell antigen—therefore patients must receive Kell-negative blood 2

Serum Protein Monitoring Interference

  • IgG kappa myeloma patients face specific challenges: Daratumumab is an IgG1 kappa antibody that produces spurious positive immunofixation results 1
  • The therapeutic monoclonal antibody band can be mistaken for the original M-protein, leading to misinterpretation of disease response 1
  • Solution: Use special interference testing or mass spectrometry-based assessment to differentiate between daratumumab and the patient's M-protein 1, 2

Minimal Residual Disease Testing

  • Daratumumab interferes with MRD monitoring by multicolor flow cytometry (due to CD38 targeting) 2

Hematologic Laboratory Abnormalities

Common Grade 3/4 Cytopenias

Based on integrated safety analysis of 1,798 daratumumab-treated patients 3:

  • Neutropenia: 45.9% (vs 32.3% comparator) - most common severe cytopenia
  • Lymphopenia: 13% (vs 7.5% comparator)
  • Thrombocytopenia: Reported in 54% of patients in CASTOR trial 2; 64.7% in real-world data 4
  • Anemia: 35.7% in real-world cohorts 4

Important caveat: When adjusted for exposure, these cytopenias occurred more frequently with daratumumab than comparators, though prevalence remained <7% except for neutropenia, lymphopenia, and pneumonia 3

Monitoring Requirements

  • CBC with differential and metabolic panel appropriate for monitoring treatment toxicities 1
  • Regular assessment needed given increased infection risk (pneumonia: 10.6% vs 7.2% grade 3/4) 3

Clinical Implications

Stem Cell Collection Considerations

  • Harvest autologous peripheral blood stem cells within first 6 cycles before prolonged daratumumab exposure in transplant candidates 1
  • Daratumumab can compromise stem cell reserve 1

Subcutaneous Formulation Note

  • Patients with significant thrombocytopenia may not be appropriate for subcutaneous daratumumab administration 1
  • Consider intravenous formulation in these cases

Infection Risk Laboratory Markers

  • Hypogammaglobulinemia reported in severe cases 5
  • Consider immunoglobulin replacement for IgG <400 mg/dL (accounting for clonal portion in IgG myeloma patients) 1

The laboratory side effects are manageable with proper pre-treatment screening and ongoing monitoring, but the blood bank interference requires proactive planning before first dose to avoid transfusion delays.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.